< Radiation Oncology < RTOG Trials


RTOG 99-10 (PROSTATE)

  • Title: A Phase III Trial to Evaluate The Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate Risk Prostate Cancer
  • Objective: To compare the efficacy of moderate-duration (28-week) neoadjuvant total androgen suppression and RT with short-duration (8-week) neoadjuvant total androgen suppression and RT as related to disease-specific survival.
  • Protocol:
    • Arm 1: TAS x 8 weeks followed by 70.2 Gy RT + concurrent TAS
    • Arm 2: TAS x 28 weeks followed by 70.2 Gy RT + concurrent TAS
  • Eligibility:
    • (cT1b-T4 and GS 2-6 and PSA 10-100) or
    • (cT1b-T4 and GS 7 and PSA <20) or
    • (T1b-T1c and GS 8-10 and PSA <20)
    • N0M0
  • Enrollment Target: 1540 patients
  • Activation: February 14, 2000
  • Closed: May 3, 2004
This article is issued from Wikibooks. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.